Strosznajder J, Samochocki M
Department of Neurochemistry, Polish Academy of Sciences, Warsaw.
J Neurochem. 1991 Oct;57(4):1198-206. doi: 10.1111/j.1471-4159.1991.tb08280.x.
Synaptoneurosomes obtained from the cortex of rat brain prelabeled with [14C]arachidonic acid [( 14C]AA) were used as a source of substrate and enzyme in studies on the regulation of AA release. A significant amount of AA is liberated in the presence of 2 mM EGTA, independently of Ca2+, primarily from phosphatidic acid and polyphosphoinositides (poly-PI). Quinacrine, an inhibitor of phospholipase A2 (PLA2), suppressed AA release by about 60% and neomycin, a putative inhibitor of phospholipase C (PLC), reduced AA release by about 30%. An additive effect was exhibited when both inhibitors were given together. Ca2+ activated AA release. The level of Ca2+ present in the synaptoneurosomal preparation (endogenous level) and 5 microM CaCl2 enhance AA liberation by approximately 25%, whereas 2 mM CaCl2 resulted in a 50% increase in AA release relative to EGTA. The source for Ca(2+)-dependent AA release is predominantly phosphatidylinositol (PI); however, a small pool may also be liberated from neutral lipids. Carbachol, an agonist of the cholinergic receptor, stimulated Ca(2+)-dependent AA release by about 17%. Bradykinin enhanced the effect of carbachol by about 10-15%. This agonist-mediated AA release occurs specifically from phosphoinositides (PI + poly-PI). Quinacrine almost completely suppresses calcium-and carbachol-mediated AA release. Neomycin inhibits this process by about 30% and totally suppresses the effect of bradykinin. Our results indicate that both phospholipases PLA2 and PLC with subsequent action of DAG lipase are responsible for Ca(2+)-independent AA release. Ca(2+)-dependent and carbachol-mediated AA liberation occurs mainly as the result of PLA2 action. A small pool of AA is probably also released by PLC, which seems to be exclusively responsible for the effect of bradykinin.
从预先用[14C]花生四烯酸[(14C)AA]标记的大鼠大脑皮层获得的突触神经小体用作研究花生四烯酸(AA)释放调节的底物和酶来源。在2 mM乙二醇双(2-氨基乙基醚)四乙酸(EGTA)存在下,大量的AA被释放,与Ca2+无关,主要来自磷脂酸和多磷酸肌醇(多-PI)。磷脂酶A2(PLA2)抑制剂奎纳克林抑制AA释放约60%,磷脂酶C(PLC)假定抑制剂新霉素使AA释放减少约30%。当两种抑制剂一起使用时表现出相加作用。Ca2+激活AA释放。突触神经小体制剂中存在的Ca2+水平(内源性水平)和5 microM氯化钙使AA释放增加约25%,而2 mM氯化钙使AA释放相对于EGTA增加50%。Ca2+依赖性AA释放的来源主要是磷脂酰肌醇(PI);然而,一小部分也可能从中性脂质中释放。胆碱能受体激动剂卡巴胆碱刺激Ca2+依赖性AA释放约17%。缓激肽使卡巴胆碱的作用增强约10 - 15%。这种激动剂介导的AA释放特异性地来自磷酸肌醇(PI + 多-PI)。奎纳克林几乎完全抑制钙和卡巴胆碱介导的AA释放。新霉素抑制这一过程约30%,并完全抑制缓激肽的作用。我们的结果表明,磷脂酶PLA2和PLC以及随后二酰甘油脂肪酶的作用负责Ca2+非依赖性AA释放。Ca2+依赖性和卡巴胆碱介导的AA释放主要是PLA2作用的结果。一小部分AA可能也由PLC释放,PLC似乎专门负责缓激肽的作用。